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Introduction: Single-nucleotide polymorphisms (SNPs) at 6q25.1 that are associated with breast cancer
susceptibility have been identified in several genome-wide association studies (GWASs). However, the exact
causal variants in this region have not been clarified.
Methods: In the present study, we genotyped six potentially functional single-nucleotide polymorphisms (SNPs)
within the CCDC170 and ESR1 gene regions at 6q25.1 and accessed their associations with risk of breast cancer in
a study of 1,064 cases and 1,073 cancer-free controls in Chinese women. The biological function of the risk variant
was further evaluated by performing laboratory experiments.
Results: Breast cancer risk was significantly associated with three SNPs located at 6q25.1—rs9383935 in CCDC170
and rs2228480 and rs3798758 in ESR1—with variant allele attributed odds ratios (ORs) of 1.38 (95% confidence
interval (CI): 1.20 to 1.57, P = 2.21 × 10−6), 0.84 (95% CI: 0.72 to 0.98, P = 0.025) and 1.19 (95% CI: 1.04 to 1.37,
P = 0.013), respectively. The functional variant rs9383935 is in high linkage disequilibrium (LD) with GWAS-reported
top-hit SNP (rs2046210), but only rs9383935 showed a strong independent effect in conditional regression analysis.
The rs9383935 risk allele A showed decreased activity of reporter gene in both the MCF-7 and BT-474 breast cancer
cell lines, which might be due to an altered binding capacity of miR-27a to the 3′ untranslated region (3′ UTR)
sequence of CCDC170. Real-time quantitative reverse transcription PCR confirmed the correlation between
rs9383935 genotypes and CCDC170 expression levels.
Conclusions: The results of this study suggest that the functional variant rs9383935, located at the 3′ UTR of
CCDC170, may be one candidate of the causal variants at 6q25.1 that modulate the risk of breast cancer.Introduction
Breast cancer is the most common female malignancy
worldwide, accounting for 23% of all the new cancer
cases in 2008 [1]. The incidence of breast cancer is rela-
tively low in China compared with Western countries
[2]. However, the incidence has increased rapidly in the
past two decades, likely due to the change in lifestyle
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unless otherwise stated.Genetic variation has been proved to be a critical factor
in discriminating cancer-susceptible individuals [4]. In
recent genome-wide association studies (GWASs), re-
searchers have identified numerous single-nucleotide
polymorphisms (SNPs) associated with breast cancer
risk in diverse populations [5]. Among these SNPs,
rs2046210, located between coiled-coil domain containing
170 (CCDC170, also called C6orf97) and estrogen receptor
1 (ESR1) at 6q25.1, was first reported to be associated with
the risk of breast cancer in Chinese populations [6]. Sub-
sequently, one intronic variant, rs3757318 in CCDC170
[7], and another intronic rs9383951 in ESR1 [8], were also
found to be associated with breast cancer risk. To date,
investigators in numerous studies have confirmed these
associations with breast cancer in this region, especially
for rs2046210 [9-12].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to breast cancer in the 6q25.1 region (encoding estrogen
receptor α), and studies have shown its implication in
breast carcinogenesis [13,14]. Nevertheless, the putative
functions of this region are still undefined. Most of the
SNPs at 6q25.1 mentioned above have mapped to in-
trons or intergenic regions. In a previous study, a 41-kb
block of the 6p25.1 region was systematically analyzed,
and significant associations with breast cancer risk
were observed for rs1038304, rs6929137, rs2046210
and rs10484919 [15]. However, these variants ae all
located upstream of the ESR1 gene region. Hence, to
evaluate the causal variants at 6q25.1 in the development
of breast cancer, we screened the potentially functional
variants at 6q25.1 within two genes (ESR1 and CCDC170)
and assessed their associations with breast cancer risk in a
case–control study including 1,064 breast cancer cases
and 1,073 controls in Chinese women in Jiangsu province
in eastern China. We further evaluated potential biological




This study included 1,064 breast cancer cases and 1,073
cancer-free controls, whose characteristics were described
previously [16]. Briefly, breast cancer patients were recrui-
ted from the First Affiliated Hospital of Nanjing Medical
University, the Cancer Hospital of Jiangsu Province and
the Gulou Hospital, Nanjing, China, between January
2004 and April 2010. Cases were diagnosed on the basis
of standard histological and clinical criteria. The estrogen
receptor (ER) and progesterone receptor (PR) status
of all breast cancer patients was determined on the
basis of immunohistochemistry (IHC) results in path-
ology reports. The controls were randomly selected
from among more than 30,000 participants in a commu-
nity-based screening program conducted in Jiangsu
province, China. The cases and controls were frequency-
matched for age (5-year interval). All participants
were genetically unrelated. After informed consent
was obtained, each individual was interviewed face-to-
face to collect information about demographic data
and menstrual and reproductive history, and approxi-
mately 5 ml of venous blood was collected. This study was
approved by the institutional review board of Nanjing
Medical University.
Single-nucleotide polymorphism selection and genotyping
In this study, we applied two approaches to select poten-
tial functional SNPs at 6q25.1. First, we focused on those
in linkage disequilibrium (LD) with the GWAS-identified
SNP rs2046210 at this region and replicated the re-
sults in another independent sample. As shown inAdditional file 1: Figure S1, a total of 30 SNPs are in LD
with rs2046210 (r2 > 0.8), which were further functionally
evaluated by SNPinfo [17] and expression quantitative
trait loci (eQTL) analyses [18]. As a result, rs3983935 in
CCDC170 was selected because it is in strong LD with
rs2046210 (r2 = 0.86) and was predicted to (1) affect a
potential binding site of microRNA-27a (miR-27a) located
in the 3′ untranslated region (3′ UTR) of CCDC170 and
(2) regulate expression of CCDC170 in the eQTL analysis.
Using another approach taking into consideration the
existence of multiple independent breast cancer suscep-
tibility loci at the 6q25.1 region and the importance of
ESR1 in breast cancer development, we also focused on
potential functional SNPs of ESR1 (chr6:152160379–
152466099). Potentially functional SNPs located in the
coding (synonymous SNPs, missense SNPs and nonsense
SNPs) and regulatory regions (promoter, 5′ UTR and 3′
UTR) were selected. The SNPs were further filtered
according to the LD analysis (r2 < 0.8) and minor allele fre-
quency (MAF) ≥0.05 in Chinese Han population. Six SNPs
of ESR1 met the criteria (Additional file 1: Figure S1), but
rs1801132 was excluded because of the failure of probe de-
sign. We also included one SNP of CCDC170 (rs9383935)
and five SNPs of ESR1 (rs488133, rs3798577, rs3798758,
rs3798757 and rs2228480). In addition, the well-known
SNP at 6q25.1, rs2046210, was selected.
Genomic DNA was isolated from leukocyte pellets of
venous blood by proteinase K digestion and followed by
phenol-chloroform extraction. All of the DNA samples
were checked for quality and quantity with a NanoDrop
2000 spectrophotometer (NanoDrop, Wilmington, DE,
USA) and by DNA electrophoresis before genotyping.
SNPs were genotyped by using Infinium BeadChip
(Illumina, San Diego, CA, USA). The call rate ranged
from 97.7% to 97.9% for six SNPs tested in all subjects.
CCDC170 3′ untranslated region luciferase plasmids
construct and site-directed mutagenesis
The CCDC170 3′ UTR containing the rs9383935 G
allele was amplified by PCR from human genomic DNA
carrying the GG homozygous genotype template with
the following primers: sense 5′-AGACGCGTTAAGT-
CAGGGGCTTTACTAGC-3′ and antisense 5′-GCAAG
CTTCTGCTGAGTAGTTGGGATTACA-3′. The PCR
products were separated in agarose gel, extracted, purified
and cloned into the pMIR-REPORT™ miRNA expression
reporter vector system (Applied Biosystems, Foster City,
CA, USA) with MluI and HindIII digestion and then were
ligated by T4 DNA ligase to the recombinant con-
structs (Additional file 2: Figure S2). The plasmid with
the rs9383935 G allele was used as the template for the
mutation G→A. The site-directed mutagenesis for the
plasmid with the A allele construct was generated
using a Mut Express Fast Mutagenesis kit (Vazyme
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constructs were sequenced to confirm the accuracy of
cloning.
Transient transfection and luciferase assays
MCF-7 and BT-474 cell lines were obtained from
Nanjing KeyGen Biotech (Nanjing, China), where they
were characterized by mycoplasma detection, DNA
fingerprinting, isozyme detection and cell vitality detec-
tion. The cell lines were maintained in growth medium
supplemented with 10% heat-inactivated fetal bovine
serum and 100 U/ml penicillin and 100 μg/ml strepto-
mycin in a 37°C incubator supplemented with 5% CO2
(MCF-7 with Dulbecco’s modified Eagle’s medium and
BT474 with RPMI 1640 medium). Cell lines were seeded
into 24-well culture plates and incubated for 24 hours
before transfection. Transfections were performed using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s protocol. The lucif-
erase plasmids (empty vector for control and vectors with
different rs9383935 alleles) were cotransfected, respect-
ively, into different cells with synthesized mature miR-
27a-3p mimic (5′-UUCACAGUGGCUAAGUUCCGC-3′)
or miRNA negative control. The pRL-SV40 plasmid (Pro-
mega, Madison, WI, USA) was also cotransfected as an
internal control. After a 24-hour incubation, Firefly and
Renilla luciferase activities were determined with the
Dual-Luciferase Reporter Assay System (Promega) on a
luminometer (BioTek, Winooski, VT, USA). Three inde-
pendent experiments with six replicates were performed
in triplicates.
Transfection of has-miR-27a-3p in MCF-7 breast cancer
cell line
The has-miR-27a mimic and the negative control RNA
duplex were transfected into MCF-7 cells seeded in six-
well plates using Lipofectamine 2000 reagent. Cells were
harvested 16 hours after transfection, and RNAs were
isolated. Two independent transfection experiments
were conducted in triplicate. Real-time PCR analysis of
mRNA levels was performed as well.
Real-time quantitative reverse transcription PCR of
CCDC170 and ESR1
Total RNAs from peripheral blood samples of 122
healthy individuals or breast cancer cell lines were ex-
tracted using TRIzol reagent (Invitrogen) according to
the manufacturer’s instructions. RNAs were reverse-
transcribed into cDNA using PrimeScript™ RT Master
Mix (TaKaRa Bio, Tokyo, Japan). Real-time quantitative
reverse transcription PCR (qRT-PCR) was carried out
with a TaqMan Gene Expression Assay (Applied Biosys-
tems) contained probes for CCDC170 (Hs00228128_m1)
and ESR1 (Hs00174860_m1). Each assay was analyzed intriplicate, and ACTB (Hs99999903_m1) was used as an
endogenous control. The threshold cycle (Ct) was deter-
mined for each assay. The relative expression levels were
calculated using the 2−ΔCt method.
Statistical analysis
Differences in demographic characteristics, selected vari-
ables and frequencies of alleles and genotypes between
the cases and the controls were analyzed by using
Student’s t-test (for continuous variables) and χ2 test
(for categorical variables). The Hardy–Weinberg equilib-
rium (HWE) for the genotype distribution of each SNP
was evaluated using the goodness-of-fit χ2 test by compar-
ing the observed genotype frequencies with the expected
ones among the controls. Logistic regression analyses
were employed to evaluate the associations between SNPs
and the risk of breast cancer by estimating the odds ratios
(ORs) and their 95% confidence intervals (CIs) with
adjustment for potential confounders such as age, age at
menarche and menopausal status. The heterogeneity of
associations between subgroups was assessed using the χ2-
based Q-test. Differences in measurements of luciferase
assays and miR-27a-3p transfection experiments between
subgroups were examined using the t-test. Differences in
the expression levels of CCDC170 and ESR1 among GG,
GA and AA genotypes of rs9383935 were assessed by
nonparametric trend test. All of the statistical analyses
were two-sided with P < 0.05 taken as the significance
level, and they were performed with SAS 9.1.3 software
(SAS Institute, Cary, NC, USA).
Results
The characteristics of the 1,064 breast cancer cases and
the 1,073 cancer-free controls have been presented else-
where [16]. In brief, age variable was comparable between
cases and controls (P > 0.05). The breast cancer cases
showed an earlier age at menarche, a later age at first live
birth and a lower proportion of natural postmenopausal
status compared with the controls (all P < 0.05). Among
the 869 patients with immunohistochemistry records for
tumor tissues, 490 cases (56.4%) were ER-positive and 506
cases (58.2%) were PR-positive.
The genotype distributions of the seven SNPs between
cases and controls and their associations with breast
cancer risk are summarized in Table 1. The observed
genotype frequencies of seven SNPs followed Hardy–
Weinberg equilibrium among the controls (P > 0.05 for
all seven SNPs). Logistic regression analysis revealed that
the minor rs9383935 A allele of CCDC170 was signifi-
cantly associated with an increased risk of breast cancer
in an additive model (per-allele OR = 1.38, 95% CI: 1.20
to 1.57, P = 2.21 × 10−6). A similar association was obser-
ved for the rs2046210 A allele (per-allele OR = 1.32, 95%
CI: 1.16 to 1.50, P = 2.04 × 10−5). In addition, the rs3798758









MAFd HWEe Additive modelf
OR (95% CI) P-value
rs9383935 151981541 CCDC170 3′ UTR G/A 414/500/149 528/439/106 0.38/0.30 0.31 1.38 (1.20 to 1.57) 2.21 × 10−6
rs2046210 151990059 Intergenic – G/A 349/517/196 447/475/150 0.43/0.36 0.19 1.32 (1.16 to 1.50) 2.04 × 10−5
rs488133 152167137 ESR1 intron G/A 867/184/11 906/160/7 0.10/0.08 1.00 1.15 (0.93 to 1.43) 0.208
rs2228480 152461788 ESR1 Thr594Thr G/A 682/340/40 633/387/49 0.20/0.23 0.34 0.84 (0.72 to 0.98) 0.025
rs3798577 152462823 ESR1 3′ UTR A/G 336/527/196 305/541/226 0.43/0.46 0.67 0.90 (0.79 to 1.02) 0.093
rs3798758 152463547 ESR1 3′ UTR C/A 520/441/98 577/425/69 0.30/0.26 0.48 1.19 (1.04 to 1.37) 0.013
rs3798757 152465936 ESR1 3′ UTR A/G 856/185/20 879/182/10 0.11/0.09 0.86 1.16 (0.95 to 1.43) 0.149
aCI, Confidence interval; OR, Odds ratio; SNP, Single-nucleotide polymorphism. bMajor/minor allele. cMajor homozygote/heterozygote/rare homozygote between
cases and controls. dMinor allele frequency (MAF) among cases/controls. e Hardy–Weinberg equilibrium (HWE) test among controls. fLogistic regression with
adjustment for age, age at menarche and menopausal status.
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breast cancer (per-allele OR = 1.19, 95% CI: 1.04 to 1.37,
P = 0.013), whereas the rs2228480 A allele of ESR1 was
associated with a decreased risk (per-allele OR = 0.84,
95% CI: 0.72 to 0.98, P = 0.025). However, no significant
associations were observed for rs488133, rs3798577 or
rs3798757. After correction for multiple testing (n = 7),
rs9383935 and rs2046210 of CCDC170 were still signifi-
cantly associated with breast cancer risk (P < 0.007).
We further evaluated the associations of rs9383935,
rs2046210, rs3798758 and rs2228480 with risk of breast
cancer by subgroups of age, age at menarche and first
live birth, menopausal status (premenopausal and nat-
ural menopausal) and subtype of breast cancer (ER and
PR status). As shown in Table 2, the associations for
rs9383935 and rs2046210 were significant in all the sub-
groups (all P < 0.05). Specifically, the association with
rs3798758 was significant among women of younger age,
older age at menarche and premenopausal status (P =
0.005, 0.022 and 0.037, respectively). For rs2228480, a
significant association was also observed in women of an
older age at both menarche and birth of first child (P =
0.005 and P = 0.048, respectively). In subtypes of breast
cancer, rs3798758 was significantly associated with risk
of ER-positive breast cancers (per-allele OR = 1.21, 95%
CI: 1.02 to 1.48, P = 0.030). Meanwhile, the rs2228480 A
allele showed a protective effect regardless of ER and/or
PR status. However, no heterogeneity was observed in
any strata of the subgroups.
To substantiate these findings, we performed logistic
regression analyses conditioned on the four significant
SNPs at 6q25.1 (Table 3). We first focused on the two
SNPs, rs9383935 and rs2046210, which were in LD
(r2 = 0.86) and passed multiple testing correction.
After adjusting for rs2046210, the data for rs9383935
remained significant (P = 0.025). In the reverse condition,
the results derived for rs2046210 showed a much weaker
association (P = 0.810). Next, we included all four SNPs inthe same model and found that the effects of rs2228480
and rs3798758 were apparently decreased after condi-
tioned on the three other SNPs (P = 0.069 and P = 0.082,
respectively), as was the result for rs2046210 (P = 0.901);
however, the effect of rs9383935 remained significant
(P = 0.019). Taken together, the results of the condi-
tional regression analysis indicated a strong independent
effect of rs9383935 on breast cancer risk in our study
population.
As predicted with RNAhybrid, miR-27a-3p has a lower
minimum free energy (MFE) with the G allele (|MFE| =
21.5 kcal/mol) of rs9383935 in CCDC170 than that with
the A allele (|MFE| = 25.1 kcal/mol) (Additional file 3:
Figure S3). Thus, we proposed that the A allele may de-
crease the expression of CCDC170, possibly by reducing
miRNA repression. Therefore, we constructed the plas-
mids containing the rs9383935 G or A allele to deter-
mine whether this variant could affect gene expression.
When we cotransfected miR-27a-3p mimic into MCF-7
cell line, we found that the activity of the reporter gene
with the rs9383935 A allele was significantly decreased
compared with that of the G allele (0.72 versus 0.28;
P = 0.012). Similar effects were observed in the BT-474
cell line (0.87 versus 0.53, P = 0.018) (Figure 1). Subse-
quently, we transfected miR-27a-3p into MCF-7 breast
cancer cells and validated its regulation of the en-
dogenous CCDC170. The qRT-PCR assay showed that
miR-27a-2p significantly decreased CCDC170 mRNA
level compared with the negative controls (P = 0.016,
Figure 2A); however, we did not find significant changes
in ESR1 expression after miR-27a-3p transcription
(P = 0.361) (Figure 2B).
To further analyze the influence of rs9383935 on gene
expression, we examined CCDC170 and ESR1 expres-
sion in 122 healthy individuals using qRT-PCR. We
found that the subjects with the risk AA genotype had
the highest level of CCDC170 expression, followed by
subjects with the GA and GG genotypes (P = 0.012)
Table 2 Stratified analysis of the associations between rs9383935, rs2046210, rs2228480 and rs3798758 with breast cancer risk
Characteristics rs9383935 P-valueb rs2046210 P-valueb rs2228480 P-valueb rs3798758 P-valueb
OR (95% CI)a P-valuea OR (95% CI)a P-valuea OR (95% CI)a P-valuea OR (95% CI)a P-valuea
Age, yr
<51 1.43 (1.19 to 1.71) 0.0001 0.556 1.36 (1.15 to 1.62) 0.0005 0.599 0.82 (0.67 to 1.02) 0.071 0.798 1.31 (1.08 to 1.57) 0.005 0.138
≥51 1.32 (1.09 to 1.60) 0.0048 1.27 (1.06 to 1.53) 0.0114 0.86 (0.68 to 1.07) 0.180 1.06 (0.86 to 1.30) 0.613
Age at menarche, yr
<16 1.39 (1.15 to 1.68) 0.0006 0.914 1.31 (1.09 to 1.57) 0.0039 0.879 0.98 (0.79 to 1.22) 0.849 0.061 1.13 (0.93 to 1.38) 0.234 0.466
≥16 1.37 (1.14 to 1.65) 0.0007 1.34 (1.12 to 1.59) 0.0012 0.73 (0.59 to 0.91) 0.005 1.25 (1.03 to 1.52) 0.022
Age at first live birth, yr
<24 1.52 (1.18 to 1.95) 0.0011 0.368 1.39 (1.09 to 1.77) 0.0077 0.621 0.91 (0.68 to 1.21) 0.505 0.611 1.21 (0.93 to 1.58) 0.152 0.730
≥24 1.32 (1.13 to 1.56) 0.0007 1.29 (1.11 to 1.51) 0.0012 0.83 (0.69 to 1.00) 0.048 1.15 (0.97 to 1.36) 0.114
Menopausal status
Premenopausal 1.37 (1.14 to 1.65) 0.0010 0.876 1.30 (1.08 to 1.55) 0.0049 0.725 0.83 (0.66 to 1.04) 0.109 0.889 1.23 (1.01 to 1.49) 0.037 0.300
Postmenopausalc 1.40 (1.15 to 1.70) 0.0008 1.36 (1.13 to 1.64) 0.0014 0.85 (0.68 to 1.06) 0.151 1.06 (0.86 to 1.30) 0.613
ER status
Positive 1.30 (1.10 to 1.53) 0.0018 0.324 1.24 (1.06 to 1.46) 0.0068 0.148 0.80 (0.65 to 0.97) 0.025 0.765 1.21 (1.02 to 1.48) 0.030 0.732
Negative 1.47 (1.23 to 1.75) 2.5 × 10−5 1.48 (1.24 to 1.76) 1.05 × 10−5 0.76 (0.61 to 0.95) 0.014 1.16 (0.96 to 1.40) 0.126
PR status
Positive 1.33 (1.13 to 1.57) 0.0005 0.618 1.31 (1.12 to 1.53) 0.0008 0.645 0.79 (0.65 to 0.96) 0.020 0.886 1.18 (0.99 to 1.41) 0.063 0.869
Negative 1.42 (1.19 to 1.70) 0.0001 1.38 (1.16 to 1.64) 0.0003 0.77 (0.62 to 0.97) 0.023 1.21 (1.00 to 1.46) 0.055














Table 3 Conditional regression analysis of rs9383935, rs2046210, rs2228480 and rs3798758
SNP Adjusted for rs9383935 Adjusted for rs2046210 Adjusted for rs2228480 Adjusted for rs3798578
OR (95% CI)a P-valuea OR (95% CI)a P-valuea OR (95% CIa P-valuea OR (95% CI)a P-valuea
rs9383935 1.37 (1.05 to 1.77)b 0.019b 1.34 (1.04 to 1.74) 0.025 1.38 (1.21 to 1.58) 1.62 × 10−6 1.38 (1.21 to 1.57) 2.11 × 10−6
rs2046210 1.03 (0.80 to 1.32) 0.810 1.02 (0.79 to 1.31)b 0.901b 1.32 (1.16 to 1.50) 1.83 × 10−5 1.31 (1.16 to 1.49) 2.72 × 10−5
rs2228480 0.83 (0.71 to 0.97) 0.018 0.83 (0.71 to 0.97) 0.020 0.86 (0.73 to 1.01)b 0.069b 0.87 (0.74 to 1.03) 0.097
rs3798758 1.19 (1.03 to 1.37) 0.016 1.19 (1.03 to 1.37) 0.016 1.15 (0.99 to 1.33) 0.062 1.14 (0.98 to 1.32)b 0.082b
aAdjusted for age, age at menarche, menopausal status where appropriate. bLogistic regression analysis conditioned on the three other single-nucleotide
polymorphisms (SNPs).
Wang et al. Breast Cancer Research 2014, 16:422 Page 6 of 9
http://breast-cancer-research.com/content/16/4/422(Figure 3A). However, we did not detect a difference in
ESR1 expression between different rs9383935 genotypes
(P = 0.238) (Figure 3B).
Discussion
The 6q25.1 region was first identified as a breast cancer
susceptibility locus in a GWAS of Chinese women [6],
which was well-replicated in subsequent follow-up studies
[12]. Rs2046210 is an intergenic variant located 29 kb
upstream of ESR1 5′ UTR and 6 kb downstream of
CCDC170 3′ UTR. eQTL analysis indicated that
rs2046210 was significantly associated with CCDC170
expression [19]. However, it has been suggested that
there is no strong evidence to support a role of SNP
rs2046210 as a functional variant regulating the expression
of CCDC170 according to the results of bioinformatics ana-
lysis from SNPinfo and RegulomeDB [20]. Nevertheless,
these findings suggest that other genetic variants highly cor-
related with rs2046210 at 6q25.1 may be functional and
may modulate individual susceptibility to breast cancer.
Recently, Cai et al. conducted luciferase assays with four
fragments from the 36-kb region harboring rs2046210,
and they found that rs6913578, in strong LD with
rs2046210 (r2 > 0.8 in CHB and European ancestry
(CEU)), might be a functional variant acting as a regulator
of enhancement [21], suggesting that genetic variants at
6q25.1 may function through modulating a transcriptionalFigure 1 Luciferase reporter assays of rs9383935 G/A in MCF-7 and B
luciferase activity than the plasmids bearing the A allele in both the MCF-7 (*
relative luciferase expression for plasmids with different alleles after normalizemechanism. In contrast, in the present study, we analyzed
functional SNPs in strong LD (r2 > 0.8) with rs2046210,
especially for those SNPs in the miRNA binding sites.
Interestingly, we found that rs9383935 highly correlated
with rs2046210 was significantly associated breast cancer
susceptibility, which result from the allele’s differential
binding affinity of miR-27a in the 3′ UTR of CCDC170 as
evaluated by luciferase assays and miRNA transfection in
breast cancer cell lines. Notably, this functional variant in
CCDC170 showed a strong independent effect, even when
well-known rs2046210 was adjusted for in the logistic
regression analysis. Moreover, qRT-PCR results confirmed
that the eQTL annotation linked rs9383935 to CCDC170
expression. CCDC170 is an uncharacterized open reading
frame (ORF) located upstream of ESR1. Several genetic
variants within this gene have been implicated in GWASs
as being associated with the risk of breast cancer and bone
mineral density [7,22-24]. For example, Dunbiers et al. ob-
served that three ORFs including CCDC170 expression
were highly correlated with ESR1 in aromatase inhibitor–
treated breast tumor and breast cancer cell lines [25]. miR-
27a is known to function as an onco-miRNA in several
cancer cell lines [26-28] and to play an important part in
cell differentiation and proliferation [28,29]. Furthermore,
overexpression of miR-27a could promote epithelial–
mesenchymal transition in cancer metastasis and could
be a promising prognostic factor in breast cancer [30].T-474 cell lines. The G allele constructs had significantly higher
P = 0.012) and BT-474 (**P = 0.018) cell lines. Shown are the mean ± SD of
d by control groups in parallel experiments.
Figure 2 Transfection of miR-27a-3p in MCF-7 breast cancer cell
line. (A) miR-27a-3p downregulated CCDC170 mRNA expression
after 16-hour transfection compared with negative control (NC)
(P = 0.016). (B) ESR1 mRNA expression was not significantly different
between the two groups (P = 0.361).
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rs9383935 may modulate individual susceptibility to breast
cancer, possibly through regulating miR-27a inhibition of
CCDC170 expression. On the basis of the above results,
rs9383935 could be considered a potential causal variant
at 6q25.1. Additional studies are needed to validate our
findings and extend the role of CCDC170 in the etiology
of breast cancers.
Researchers in numerous studies have evaluated the
associations between variants in ESR1 and breast cancer
risk [31,32]. As mediated by estrogen, ERα can directly
bind to estrogen response elements or indirectly interacts
with chromatin through tethering to other transcription
factors, such as coactivators or corepressors [13]. Clinical
and epidemiological studies have shown that ERα affects
cancer initiation, progression and response to treatment,
especially in breast cancer [14]. In a previous study, we con-
ducted a meta-analysis in diverse populations and providedFigure 3 Correlation of rs9383935 genotypes with CCDC170 and ESR1evidence for associations between two SNPs (rs2234693,
rs1801132) of ESR1and breast cancer susceptibility [31]. In
a follow-up study, we performed a case–control study with
878 cases and 900 controls on rs2234693 and rs1801132
validated the association of rs2234693 with breast
cancer risk in Chinese women (OR = 0.85, 95% CI:
0.74 to 0.98, P = 0.024), but not for rs1801132 [15].
As an extension of our previous studies, in the present
study we evaluated potentially functional SNPs of ESR1
in a larger sample size comprising 1,064 cases and 1,073
controls. We found significant associations of rs3798758
and rs2228480 with breast cancer risk Chinese women.
The SNP rs2228480, located in exon 8 of ESR1, is a syn-
onymous variant. The exon 8 involves in the assembling
of the C-terminal region of ERα [33]. This region modu-
lates interaction between ERα and other transcription
factors, likely to change the affinity of ERα with DNA
[33]. Although synonymous variants do not change
amino acid sequences, accumulated evidence indicates
that these variants can modify mRNA splicing, stability,
structure and translation process [34]. For example,
Nackley et al. showed that diverse mRNA secondary
structures with different stability were correlated to pro-
tein expression levels [35]. Another SNP, rs3798758, may
also influence miRNA binding, including miR-383, a
negative regulator of proliferation [36]. Nevertheless, in
the present study, both of these two SNPs showed weak
effects in our multivariate logistic regression analysis,
which failed to show their independent associations with
breast cancer risk. However, some variants in intron re-
gions which might be involved in alternative splicing or
enhancer manipulation were not included in the present
study. Additional investigations focused on these regions
are warranted to expand the understanding of 6q25.1 in
breast cancer susceptibility.
Conclusions
Overall, in the present study, we evaluated six potentially
functional SNPs within the 6q25.1 region and confirmedrelative expression. (A) P = 0.012. (B) P = 0.238.
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http://breast-cancer-research.com/content/16/4/422that rs9383935, rs3798758 and rs2228480 were associ-
ated with breast cancer in Chinese women, and we also
replicated rs2046210 in accordance with previous reports.
Specifically, the CCDC170 rs9383935 showed the most
prominent effect of any other variants of ESR1 or
rs2046210, which provides new evidence for the role of
the 6q25.1 region in breast cancer susceptibility. Further
functional investigations of CCDC170 and 6q25.1 are war-
ranted to fully reveal the mechanisms underlying the ob-
served association with risk of breast cancer.
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Additional file 1: Figure S1. Overview of the 6q25.1 region
(chr6:151767683–152466099) from the UCSC Genome Browser (NCBI36/
hg18). The upper panel shows the 698.4-kb region in 6q25.1 contain four
genes: RMND1, C6orf211, CCDC170 and ESR1. The lower panel shows
linkage disequilibrium (LD) plots of 31 SNPs in LD with rs2046210 and 6
selected functional SNPs marked with an asterisk. LD values between
SNPs as indicated in the diamonds were measured by r2 in Chinese
descent (CHB). For example, the r2 value between rs2046210 and
rs9383935 was 0.86 in CHB.
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rnahybrid/). Different alleles of rs9383935 are marked with squares.
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